Chevron Corporation (CVX) vs Eli Lilly and Company (LLY)
See how Chevron Corporation and Eli Lilly and Company differ across market data and performance, so you can decide which asset best fits your strategy.
$187.38
NYSE
Chevron Corporation is an integrated energy company engaged in worldwide oil and gas exploration, production, and refining. It is the second-largest oil company in the United States, reporting 2025 net oil-equivalent production of 3.7 million barrels per day, including 8.5 billion cubic feet of natural gas per day and 2.3 million barrels of liquids per day. The company produces energy across North America, South America, Europe, Africa, Asia, and Australia. Chevron’s refining network is concentrated in the United States and Asia, with total global refining capacity of 1.8 million barrels per day at year-end 2025. At the end of 2025, net proved reserves totaled 10.6 billion barrels of oil equivalent, including 5.7 billion barrels of liquids and 29.2 trillion cubic feet of natural gas.
Eli Lilly & Co. is a pharmaceutical company focused on neuroscience, cardiometabolic disease, oncology, and immunology. Its leading products include Verzenio and Jaypirca in cancer treatment; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin in cardiometabolic care; and Taltz and Olumiant in immunology.